Form 8-K Adamis Pharmaceuticals For: Mar 21
- Stocks dip after weak U.S. confidence data; oil climbs
- Earnings Estimates are 'Likely Too Optimistic', Risk Not Fully Reflected - Goldman
- Apple's (AAPL) Runs into 5G Modem Development Issues, Will Continue to Use Qualcomm (QCOM) - Analyst
- Bank of America Clients are Selling This Rally
- Recession Could Push Apple Stock 27% Down Says Evercore ISI and Cuts Price Target
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect
San Diego, March 21, 2022 – Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-Filled Single-Dose Syringes to the consumer level. The batches in the table below are being recalled due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes SYMJEPI in the United States, under license from Adamis, the NDA holder. USWM will handle the entire recall process for Adamis, with Adamis oversight. SYMJEPI is manufactured and tested for Adamis by Catalent Belgium S.A.
If a person is experiencing an allergic reaction and/or anaphylaxis and is unable to access life-saving epinephrine due to the syringe malfunction, it can lead to life threatening consequences including death. Although not confirmed to be related to the recall, there have been two different customer complaints on three syringes, regarding difficulty in dispensing the product, to date. However, neither US WorldMeds nor Adamis Pharmaceuticals has received, or is aware of, any adverse events related to this recall.
The recall encompasses all of the following batches, within expiry:
|SYMJEPI (epinephrine) Injection||0.15 mg/0.3 mL||78670-131-02||21101Y||11/30/2022|
|0.3 mg/0.3 mL||78670-130-02||21041W||8/31/2022|
SYMJEPI is indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets, and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
The products are packaged in 2-count Pre-Filled Single-Dose Syringes per carton and were distributed nationwide in the USA and directly to customers and/or medical facilities. The products can be identified by the label containing the US WorldMeds name and logo pictured on the cartons in the links below.
US WorldMeds is notifying its customers by email, FDA alerts, and direct outreach. Consumers and institutions that have products that are subject to this recall should stop using the products immediately and may either return or discard the recalled lots. Consumers with questions regarding this recall can call (888) 900-8796 or e-mail questions at [email protected] Monday-Friday from 8:00 am to 4:00 pm ET.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
|·||Complete and submit the report Online|
|·||Regular Mail or Fax: Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178|
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Quality Compliance Partners
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Illinois American Water Celebrates Safety Excellence Milestones in the Company’s Southern Illinois Service Area
- Leaders Across Industries Targeted for Blockchain Business Imperative via Maryland Smith Second Cohort for Synchronous Online Program Begins July 11
- Green Life Farms Continues Innovation at Babcock Farm
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!